Mandate

Vinge advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio

February 03, 2011

Vinge has advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio for approximately SEK 2.2 billion. The portfolio consists of 57 properties spread over 42 locations in Sweden. Almost 80 per cent of the rental income emanates from public authorities. Several of the properties have a market value of between SEK 5-40 million, although the portfolio also includes large properties such as the premises occupied by the Swedish Migration Board in Norrköping (Presidenten 1), the municipal council building in Haninge (Söderbymalm 3:486) and Sollentuna police station (Transporten 2). The portfolio comprises a total of 300,000 sq. m. and most of the lettable area consists of office space.

Vinge’s team consisted of partner Patrick Forslund and associates Niclas Winnberg and Daniel Unger.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024